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Purpose. To investigate cardiomyopathy in offspring in a mouse model of pregestational type 1 diabetic pregnancy. Methods.
Pregestational diabetes was induced with STZ administration in female C57BL6/J mice that were subsequently mated with healthy
C57BL6/J males. Offspring were sacrificed at embryonic day 18.5 and 6-week adolescent and 12-week adult stages. The size and
number of cardiomyocyte nuclei and also the extent of collagen deposition within the hearts of diabetic and control offspring were
assessed following cardiac tissue staining with either haematoxylin and eosin or Picrosirius red and subsequently quantified using
automated digital image analysis. Results. Offspring from diabetic mice at embryonic day 18.5 had a significantly higher number of
cardiomyocyte nuclei present compared to controls.These nuclei were also significantly smaller than controls. Collagen deposition
was shown to be significantly increased in the hearts of diabetic offspring at the same age. No significant differences were found
between the groups at 6 and 12 weeks. Conclusions. Our results from offspring of type 1 diabetic mice show increased myocardial
collagendeposition in late gestation andhave increasedmyocardial nuclear counts (hyperplasia) as opposed to increasedmyocardial
nuclear size (hypertrophy) in late gestation. These changes normalize postpartum after removal from the maternal intrauterine
environment.
1. Introduction
Diabetes mellitus is a common complication in pregnancy
and is estimated to affect 2–5% of pregnant women [1].
Preexisting type 1 diabetes and preexisting type 2 diabetes
account for 0.27% and 0.1% of births, respectively, and these
figures are increasing globally [1].Themajority of pregnancies
complicated by diabetes are a result of gestational diabetes
(87.5%); the remaining 7.5% and 5% are due to pregestational
type 1 and type 2 diabetes, respectively. Pregestational type 1
and type 2 diabetes are more serious and are responsible for
greater adverse pregnancy outcomes [1, 2].
Parallel to the increasing global incidence of diabetes, the
number of childbearing females presenting with pregesta-
tional diabetes is increasing.Maternal pregestational diabetes
represents an arduous environment for embryonic and fetal
development. Indeed, despite the improved obstetric care
and better management of maternal hyperglycaemia over
the last few decades, perinatal mortality and congenital
abnormality rates still remain several-fold higher in preg-
nancies complicated by diabetes than in the background
population [1–4]. Unlike gestational diabetes which occurs
during midgestation, the stressors associated with pregesta-
tional diabetes are present during the first, most sensitive
periods of fetal development, including the crucial period of
organogenesis in the first trimester. An adaptive response by
the fetus may result in and could contribute to modification
of key metabolic processes and developmental organization,
resulting in congenital defects and altered growth trajectories.
Among the numerous congenital malformations that
have been associated with maternal pregestational diabetes,
cardiovascular defects are the most frequent [5]. In a large
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prospective study of 192,618 live births in the UK, cardio-
vascular malformations were confirmed in 3.6% of babies
born to pregestational diabetic mothers compared to 0.74%
of babies born to nondiabetic mothers. This represented a
fivefold increase in the risk of cardiovascular malformations
in offspring of pregestational diabetic mothers [6]. Among
the variety of cardiovascular malformations that can arise
in these offspring hypertrophic cardiomyopathy represents
a very common outcome. It has been shown to affect up to
75% of foetuses in utero and 40% of infants of pregestational
diabetic mothers and can cause clinical symptoms in 5% [7–
11]. Ullmo et al. described the diabetic foetal heart as being
threatened in a double fashion [12]. Firstly, during the first
trimester diabetes has a teratogenic effect on cardiogenesis
by impairing the correct expression of genes coding for
cardiac development [12–14]. Secondly, at the end of the
second trimester or beginning of the third trimester, the
fetus may be affected by hypertrophic cardiomyopathy. It
has been shown that normally formed stillborn infants of
diabetic mothers, when compared with appropriately grown
stillborn nondiabetic infants, had heavier hearts and thicker
ventricular free wall measurements when adjusted for birth
weight [15]. Additionally there is data to suggest that offspring
of pregestational diabetes are at an increased risk of cardio-
vascular disease later in life [16–18].
The aim of this study is to investigate mechanisms of
offspring cardiomyopathy in pregestational type 1 diabetic
pregnancy in a mouse model.
2. Materials and Methods
2.1. Generating aMouseModel of Type 1 Diabetes in Pregnancy.
Institutional ethical approval and Irish government licensing
were obtained for all procedures. For all experiments the
“Principles of laboratory animal care” (NIH publication
number 85-23, revised 1985) were followed throughout. Type
1 diabetes was induced in female C57BL6/J mice using
intraperitoneal streptozotocin (STZ) injections. A total of
54 female mice received STZ injections; these were divided
into 6 groups and STZ injections were given to mice in each
group on 6 different occasions. The first group (𝑛 = 10)
received 50mg/kg STZ over 5 consecutive days, with group
2 receiving a dosage regime of 75mg/kg over 3 consecutive
days. As there was a similar response to both STZ dosing
regimes, we continued with the latter regime which resulted
in fewer injections and less stress for the animals. Forty-four
females received an STZ dose of 75mg/kg/3 days. Diabetes
was confirmed in female mice before pregnancy by taking
fasting glucose measurements over two days. Diabetes was
diagnosed when a fasting glucose was >11mmol/L on two
separate days. Blood was obtained via tail venipuncture
and measured using an Accu-chek compact plus system
(Hoffmann-La Roche Ltd. http://www.accu-chek.com/us/).
Female C57BL6/J mice were mated with nondiabetic male
C57BL6/J mice. The day of detection of a vaginal plug was
designated E0.5 (embryonic day 0.5) when females were
placed in an individual cage for the rest of the pregnancy.
Healthy nondiabetic female C57BL6/J mice mated with
nondiabetic C57BL6/J males acted as a control group. Mean
fasting glucose prepregnancy in diabetic mice compared to
controls was 13.5±1.0 versus 5.4±0.44mmol/L, and towards
the end of pregnancy (E16.5) it was 21.7mmol/L ± 6.3 versus
5.3 ± 0.44mmol/L.
2.2. Histology. In order to obtain histological data from
embryonic hearts, pregnant animals were sacrificed at E18.5
using cervical dislocation while being under heavy sedation
(3% isoflurane). Once death was confirmed the maternal
abdomen was opened using 30∘ angled scissors. Embryos
were removed from the uterus and placed on iced phosphate
buffer saline (PBS). Embryos were removed from the individ-
ual yolk sac using iridectomy scissors and hearts from the 6-
and 12-week-old mice were excised. All samples were fixed
in 10% formalin for a minimum of 24 hours, processed, and
subsequently paraffin-embedded. Five𝜇m sections were cut
using a microtome and mounted onto poly-l-lysine-coated
glass slides. Samples were stained with either haematoxylin
and eosin (H&E) or Picrosirius red using a Leica autostainer
XL. The nuclear stain haematoxylin enables measurement
of the number and size of nuclei. Picrosirius red detects
collagen isoforms 1 and 3, which reflects the presence and
extent of any abnormal collagen deposition in the offspring
hearts. The Picrosirius red staining procedure involved both
automated (Leica autostainer XL) andmanual steps. Sections
were deparaffinised and hydrated in the Leica autostainer and
then placed in 5% phosphomolybdic acid (PMA). Sections
were then rinsed in distilled water before being placed in
picrosirius red (1 : 1000 dilution; Direct red 80 (25%) in
picric acid). Sections were then transitioned from 0.4%
hydrochloric acid (HCL) to 70% ethanol before dehydration
in the Leica autostainer.
2.3. Aperio ScanScope XT High Throughput Scanning System.
The Aperio ScanScope XT system (http://www.aperio.com)
is capable of scanning glass slides at 20x or 40x magnification
to create seamless, true-colour digital slide images. The main
advantage of this type of image analysis is the inherent
objectivity which excludes potential errors associated with
manual scoring and analysis; it also provides the facility to
perform batch analysis and the use of associated analysis soft-
ware (Spectrum). Spectrum tools allow the user to annotate,
extract, highlight, and analyse the whole slides or specific
regions with the use of a comprehensive image analysis
algorithm library. To investigate the possible presence of
cardiomyocyte hyperplasia and/or hypertrophy, a nuclear
algorithm was modified and applied to the scanned H&E
stained slides.The algorithmcalculated twomain parameters,
(1) the number of myocyte nuclei and (2) the size of myocyte
nuclei. Following optimisation with the algorithm settings on
theAperio software, the following size exclusion settingswere
selected to ensure only myocyte nuclei were assessed: mini-
mum nuclear size, 10 𝜇m2; minimum nuclear size, 162 pixels;
minimum compactness, 0.22; minimum elongation, 0.25.
To investigate the extent of collagen deposition in offspring
hearts, Picrosirius red staining was used. A positive pixel
count algorithm was used to automatically quantify the area
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Figure 1: Histological images of six-week-old offspring of type 1 diabetic mouse demonstrating the application of the Aperio software. (a)
Full image taken with Aperio digital scanning microscope. LV: left ventricle wall; RV: right ventricle wall; IVS: interventricular septum. (b)
Mark-up image showing the detection of collagen by the Aperio positive pixel count algorithm. Blue represents negative background and
yellow/orange represents positive collagen detection, as shown in corresponding 40x magnified images.
occupied by the dark pink stain colors representing collagen
within each scanned slide image (Figure 1(a)). Calibration of
individual staining patterns was performed by specifying the
requisite colour (range of hues and saturation) and limits
for the desired intensity range. Required input parameters
for each stain were based on the HSI (hue, saturation, and
intensity) colour model. To detect the dark pink colour of
collagen with Picrosirius red, a hue value of 0.8 was specified.
The hue width value of 0.5 was used to allow inclusion of a
moderate range of colour shades. A collagen volume fraction
was calculated based on the percent of dark pink collagen
staining quantified within a tissue section.
2.4. Statistical Analysis. The SPSS 18 statistics package was
used to perform statistical analysis. The data were normally
distributed and independent two-tailed equal variance 𝑡-tests
were used when comparing the two groups. A 𝑃 value of
<0.05 was considered to be significant.
3. Results
3.1. Cardiomyocyte Nuclei Size. Analysis with the nuclear
algorithm shows that offspring of diabetic mothers have
significantly smaller nuclei (defined by pixilation) than the
control mice at embryonic day 18.5 (235 ± 125 versus 316 ±
82; 𝑃 < 0.05). The same difference was not found at 6 and
12 weeks of age (Figure 2). Furthermore, when all age groups
were pooled into their relevant groups (diabetic or control), a
significant difference was still present. Diabetic nuclei were
significantly smaller than control nuclei (272 ± 101 versus
312 ± 66; 𝑃 < 0.05) (Figure 2).
3.2. Cardiomyocyte Nuclear Number. There was a significant
increase in cardiomyocyte nuclei number in diabetic off-
spring at embryonic day 18.5 (E18.5) compared to controls
(11440 ± 5401 versus 8279 ± 3058; 𝑃 < 0.05). No significant
difference was found between the groups at 6 and 12 weeks of
age (Figure 3).
When analysing the relationships between nuclear fea-
tures and echocardiography parameters, significant corre-
lations were only observed when combining data from
the 6- and 12-week groups. A positive correlation between
increasing nuclei number and increasing interventricular
septal thickness (IVS) was observed (Pearson correlation:
0.598∗; R2 linear: 0.358; 𝑃 < 0.05).
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Figure 2: Comparison of cardiomyocytes nuclear size. Cardiac
tissues derived from offspring of control and diabetic groups from
E18.5 (white bars), 6 weeks (grey bars), and 12 weeks (bars) of age
were stained with haematoxylin and eosin. Slides were digitally
scanned and the nuclear size of the cardiomyocytes was calculated
using a modified algorithm fromAperio. Mean nuclear area (𝜇M) is
presented. ∗𝑃 < 0.05.
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Figure 3: Comparison of cardiomyocytes nuclear number. Cardiac
tissues derived from offspring of control and diabetic groups from
E18.5 (white bars), 6 weeks (grey bars), and 12 weeks (bars) of age
were stained with haematoxylin and eosin. Slides were digitally
scanned and the number of nuclei of the cardiomyocytes was
calculated using a modified algorithm from Aperio. Mean nuclear
number is presented. ∗𝑃 < 0.05.
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Figure 4: Comparison of the degree of collagen deposition. Cardiac
tissues derived from offspring of control and diabetic groups from
E18.5 (white bars), 6 weeks (grey bars), and 12 weeks (bars) of age
were stained with Picrosirius red to assess the extent of collagen
deposition. Slides were digitally scanned and a positive pixel count
algorithm was used to automatically quantify the area occupied
by the dark pink stain colors representing collagen. The collagen
volume fraction was calculated and is presented. ∗𝑃 < 0.05.
3.3. Collagen Deposition. Histological analysis of collagen
volume fraction revealed that there was a significant increase
in collagen deposition present in the myocardium of diabetic
offspring at embryonic day 18.5 (E18.5) compared to controls
(1.33 ± 0.28 versus 0.62 ± 0.60; 𝑃 < 0.05). This difference was
not present at 6 and 12 weeks of age (Figure 4).
4. Discussion
This study shows that myocardial samples from offspring
of pregestational type 1 diabetic pregnancies display nuclear
characteristics of myocyte hyperplasia as opposed to hyper-
trophy. Cardiac myocyte nuclei were smaller and more
numerous in late gestation (embryonic day 18.5) compared
to control offspring. The results also show an increase in
collagen deposition in the hearts of offspring of pregestational
type 1 diabetic pregnancy in late gestation (embryonic day
18.5). These alterations in cardiomyocyte nuclei size and
number and collagen deposition were shown to normalize
and return to control levels by 6 and 12 weeks, representing
adolescence and adulthood, respectively.
Hyperplasia is the main mechanism involved in cardiac
development in utero, soon after birth hypertrophy takes over
as themainmechanism bywhich cardiacmass increases.This
increase in cardiac mass is a characteristic of hypertrophic
cardiomyopathy and is mediated by an increase in the total
mass of the myocytes and in the total mass of interstitial
fibrosis. Previous studies have shown that embryos and
Journal of Diabetes Research 5
neonates from diabetic pregnancy experience enlargement of
the heart and postulated that this was due to a combination
of hypertrophy and hyperplasia of the cardiomyocytes and
fibroblasts [12, 15, 19]. Our results show increased numbers
of cardiac myocyte nuclei and increased collagen deposition
in the offspring of pregestational diabetics. These findings
support the hypothesis that hyperplasia is the main mecha-
nism involved in the increase in cardiac mass in late gestation
and cardiomyocyte hypertrophy plays a less significant role in
the development of foetal hypertrophic cardiomyopathy. In
addition, correlations with echocardiography data highlight
a significant positive correlation between nuclei number and
interventricular septal thickness. This result further suggests
that there may be a link between cardiomyocyte number
and hypertrophic cardiomyopathy, possibly inferring a role
for increased hyperplasia in hearts of offspring from type 1
diabetic mothers, although further studies would be required
to confirm this hypothesis.
Studies have shown that the diabetic intrauterine environ-
ment is characterised by increased reactive oxygen species
[20–22], and these have been shown to directly impair
contractile function [23] and affect myocardial development
bymeans of activatingmany downstream signalling pathways
involved in myocardial growth, matrix remodelling, and
cellular dysfunction [20, 22]. ROS have also been shown
to activate matrix metalloproteinases and embryonic fibrob-
lasts, both of which lead to increased collagen and fibronectin
deposition [22, 24]. In mid-to-late gestation embryos begin
producing their own insulin to regulate glycaemia and
growth. Unfortunately this process quickly changes from a
helpful mechanism needed for ameliorating high levels of
circulating blood glucose to one of a pathogenic accomplice
to hyperglycemia. High levels of foetal insulin are produced
in response to high levels of circulating blood glucose.
This results in rapid foetal growth and offspring born large
for gestational age, known as macrosomia. Foetal hyperin-
sulinemia has also been associated with the development
of hypertrophic cardiomyopathy [25, 26]. Insulin has been
shown to stimulate fibroblast proliferation [27], which again
may lead to increased collagen deposition. However, the
activation of cardiac fibroblasts can have a direct effect on
the number of cardiomyocytes. Ieda et al. found that embry-
onic cardiac fibroblasts induced the proliferation of car-
diomyocytes [28]. They identified fibronectin, collagen, and
heparin-binding EGF-like growth factor as embryonic car-
diac fibroblast specific signals that collaboratively promoted
cardiomyocyte proliferation through 𝛽1 integrin signalling in
a paracrine fashion [28]. It has been shown that normally
formed stillborn infants of diabetic mothers, when compared
with appropriately grown stillborn nondiabetic infants, had
heavier hearts and thicker ventricular freewallmeasurements
when adjusted for birth weight [15]. Biochemical markers
of cardiac dysfunction (Pro-B-type natriuretic peptide and
Troponin-T) have also been shown to be elevated in infants of
diabetic mothers, especially those with cardiomyopathy and
poor perinatal outcome [29].
Our group previously identified global cardiac hypertro-
phy in late gestation (embryonic day 18.5) of diabetic preg-
nancy with ultrasound [11, 15, 30]. Increased interventricular
septal and posterior wall thickness was observed in late
pregnancy of pregestational diabeticmothers.Wehave shown
in this present study that the structural alterations found
in embryos of late stage diabetic pregnancy may be due to
excessive cardiomyocyte hyperplasia and increased collagen
deposition resulting from cardiac fibroblast cell activity.
These processes may be due to the pregestational diabetic
intrauterine environment characterized by hyperglycemia,
increased reactive oxygen species production, and foetal
hyperinsulinemia.
Although previous studies have postulated that car-
diomyocyte hypertrophy and hyperplasia in addition to
fibrosis were the means by which cardiac mass increases;
to our knowledge this is the first study to show that it is
cardiomyocyte hyperplasia that plays a much more central
role in this pathogenesis as opposed to hypertrophy. This
is in addition to increased collagen deposition. This study
provides a novel insight into the cardiac changes that may
occur in the embryos of a mouse model of pregestational
type 1 diabetic pregnancy. One limitation to the study is the
relatively low numbers of subjects available for examination,
as cohorts of animals were sacrificed for different experi-
mental procedures. Future research may benefit from larger
numbers to improve statistical power and also investigate
cardiac fibroblast activity, as these cells have shown to be
important players in the development of cardiomyopathies.
5. Conclusion
This data suggests that pregestational type 1 diabetes impacts
offspring cardiomyocyte development resulting in increased
cardiomyocyte proliferation and increased cardiac fibroblast
activity. These changes appear to resolve by adolescence but
may contribute to an increased risk of cardiovascular disease
in later life.
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